Results 1 to 10 of about 98,354 (197)

Experience of research nurses with oral encochleated amphotericin B for treatment of cryptococcal meningitis in a resource-limited setting [PDF]

BMC Infectious Diseases
Background Besides the commonly used intravenous formulations of amphotericin B, an oral nanocrystal amphotericin B (MAT2203) formulation is being evaluated for efficacy to treat invasive fungal infections.
Cynthia Ahimbisibwe, Richard Kwizera, Jane Frances Ndyetukira, Olivie Carolyne Namujju, Alisat Sadiq, Mucunguzi Atukunda, Caleb P. Skipper, David R. Boulware, David B. Meya   +8 more
doaj   +2 more sources

Amphotericin-B in dermatology

Indian Dermatology Online Journal, 2022
Akash Agarwal, Bikash R Kar
doaj   +3 more sources

Antifungal effects of andrographolide and its combination with amphotericin B against selected fungal pathogens. [PDF]

PeerJ
Dafur GS, Tuan Kub TN, Banga Singh KK, Harun A, Lambuk F, Mohamud R, Kadir R, Ismail N, Yusop N.   +8 more
europepmc   +3 more sources

Amphotericin B Revisited

MAMC Journal of Medical Sciences, 2021
Amphotericin B, one of the first systemic antifungal agents, has been in use since the past six decades. In light of the recent outbreak of mucormycosis (black fungus) cases during the second coronavirus disease 2019 wave in India, the relevance of ...
Sahil Kumar, Vandana Roy
doaj   +1 more source

Amphotericin B induced pancytopenia

Journal of Family Medicine and Primary Care, 2022
Amphotericin B (AMB) has been the irreplaceable drug of choice for countless fungal and protozoal infections. One of the lesser-known adverse effects of AMB is Pancytopenia - very rare with very few cases reported - most commonly observed following ...
Esha Vaish, Kamlesh K Gupta, Shahnawaz A Ansari, Kaushal K Singh   +3 more
doaj   +1 more source

Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?

Journal of Fungi, 2020
As the oldest and for many decades the only available agent for the treatment of life-threatening invasive fungal diseases, amphotericin B (AmB) is known for its broad-spectrum fungicidal activity against a wide range of yeasts and molds.
Maria Aigner, Cornelia Lass-Flörl
doaj   +1 more source

An Amphotericin B Derivative Equally Potent to Amphotericin B and with Increased Safety. [PDF]

PLoS ONE, 2016
Amphotericin B is the most potent antimycotic known to date. However due to its large collateral toxicity, its use, although long standing, had been limited. Many attempts have been made to produce derivatives with reduced collateral damage.
Armando Antillón, Alexander H de Vries, Marcel Espinosa-Caballero, José Marcos Falcón-González, David Flores Romero, Javier González-Damián, Fabiola Eloísa Jiménez-Montejo, Angel León-Buitimea, Manuel López-Ortiz, Ricardo Magaña, Siewert J Marrink, Rosmarbel Morales-Nava, Xavier Periole, Jorge Reyes-Esparza, Josué Rodríguez Lozada, Tania Minerva Santiago-Angelino, María Cristina Vargas González, Ignacio Regla, Mauricio Carrillo-Tripp, Mario Fernández-Zertuche, Lourdes Rodríguez-Fragoso, Iván Ortega-Blake   +21 more
doaj   +1 more source

Identifying genetic variants associated with amphotericin B (AMB) resistance in Aspergillus fumigatus via k-mer-based GWAS

Frontiers in Genetics, 2023
Aspergillus fumigatus is one of the most common pathogenic fungi, which results in high morbidity and mortality in immunocompromised patients. Amphotericin B (AMB) is used as the core drug for the treatment of triazole-resistant A. fumigatus.
Meng-Meng Chen, Meng-Meng Chen, Guo-Hui Shi, Yi Dai, Yi Dai, Wen-Xia Fang, Qi Wu, Qi Wu   +7 more
doaj   +1 more source

Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B. [PDF]

PLoS ONE, 2014
The polyene antifungal agent Amphotericin B exhibits potent and broad spectrum fungicidal activity. However, high nephrotoxicity can hinder its administration in resource poor settings.
Dithi Banerjee, Lauren Burkard, John C Panepinto   +2 more
doaj   +1 more source

Comparative pharmacokinetics of amphotericin B after single- and multiple-dose administration of G-ABCD and conventional amphotericin B deoxycholate to rats

Journal of Global Antimicrobial Resistance, 2020
Objective: G-ABCD is a biosimilar product of amphotericin B colloidal dispersion (ABCD). This study was designed to systematically examine the plasma pharmacokinetics (PK) and tissue distribution of G-ABCD in rats, using amphotericin B deoxycholate (DAmB)
Huanhuan Qi, Xueyuan Zhang, Hao Feng, Yating Xiong, Yuancheng Chen, Jing Zhang, Chunlei Li   +6 more
doaj   +1 more source